Tiazofurin

Clinical data
Other names	2-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-thiazole-4-carboxamide
ATC code	L01XX18 (WHO)
Identifiers
IUPAC name (1R)-1-[4-(aminocarbonyl)-1,3-thiazol-2-yl]-1,4-anhydro-D-ribitol
CAS Number	60084-10-8 N
PubChem CID	457954
ChemSpider	403014 Y
UNII	ULJ82834RE
ChEMBL	ChEMBL108358 Y
CompTox Dashboard (EPA)	DTXSID00208827
Chemical and physical data
Formula	C9H12N2O5S
Molar mass	260.26 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(c1nc(sc1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO)N
InChI InChI=1S/C9H12N2O5S/c10-8(15)3-2-17-9(11-3)7-6(14)5(13)4(1-12)16-7/h2,4-7,12-14H,1H2,(H2,10,15)/t4-,5-,6-,7-/m1/s1 Y Key:FVRDYQYEVDDKCR-DBRKOABJSA-N Y
NY (what is this?)  (verify)

Tiazofurin is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. Tiazofurin and its analogues were under investigation for potential use in the treatment of cancer,^[1] though side effects such as pleuropericarditis and a flu-like syndrome precluded further development. They also show antiviral effects and may be reevaluated as potential options in the treatment of newly emerging viral diseases.^[2]

The treatment of 1-O-Acetyl-2,3,5-tri-O-benzoyl-beta-D-ribofuranose [6974-32-9] (1) with trimethylsilyl cyanide gives 2,3,5-Tri-O-benzoyl-beta-D-ribofuranosyl cyanide [23316-67-8] (2). Treatment with hydrogen sulfide led to (2R,3R,4R,5R)-2-((Benzoyloxy)methyl)-5-carbamothioyltetrahydrofuran-3,4-diyl dibenzoate, PC10907289 (3). Cyclization with Ethyl bromopyruvate [70-23-5] (4) led to 2-(2,3,5-Tri-O-benzoyl-beta-D-ribofuranosyl)-4-thiazolecarboxylic Acid Ethyl Ester [60084-09-5] (5). Removal of the protecting groups with sodium methoxide afforded 2-beta-D-Ribofuranosyl-4-thiazolecarboxylic Acid Ethyl Ester [95936-53-1] (6). Amide-ester interchange by treatment with dry ammonia completed the synthesis of Tiazofurin (7).